Skip to content
DataLookout
Menu

NCT07830199

A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 2026 to Oct 20, 2026
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adverse events (AEs)
Timeframe: From Day 1 to 40 days after last dose.
Dose-limiting toxicity (DLT)
Timeframe: From Day 1 to 12 months.
Maximum Tolerated Dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended Phase 2 Dose (RP2D)
Timeframe: From Day 1 to 12 months.

Secondary (5)

Progression free survival (PFS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)
Overall survival (OS)

Arms and interventions

SHR-4595 GroupExperimental

SHR-4595 for Injection, in different stages with different doses.

Drugs: SHR-4595 for Injection

Sites

2 sites in 1 country